Education
About Us
Working with TipRanks
Follow Us
ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥2,942.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥61.93B
Enterprise Value¥74.11B
Total Cash (Recent Filing)¥7.23B
Total Debt (Recent Filing)¥13.77B
Price to Earnings (P/E)8.6
Beta0.50
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)59.10
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.00
Price to Sales (P/S)1.02
P/FCF Ratio-137.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)183.1
Revenue Forecast (FY)¥69.09B
Bulls Say, Bears Say
Bulls Say
Consistent Multi-year Revenue GrowthSustained revenue expansion over multiple years indicates durable demand for ASKA’s prescription portfolio and successful lifecycle management. This supports predictable cash flows, funds ongoing R&D and commercialization, and strengthens bargaining position with distributors over a 2–6 month horizon and beyond.
High Gross Profit MarginsNear-50% gross margins reflect structural pricing power and cost-efficient manufacturing in specialty pharmaceuticals. High gross margins provide a lasting buffer to absorb higher R&D and regulatory costs, enabling reinvestment into pipelines and preserving operating leverage over medium-term planning cycles.
Reduced Leverage And Strong Equity RatioA materially lower debt-to-equity and high equity ratio improve financial flexibility and lower interest and covenant risk. This structural balance-sheet strength enhances resilience to shocks, supports capital allocation for M&A or clinical programs, and reduces refinancing pressure over time.
Bears Say
Declining Net Profit Margins In 2025A meaningful drop in net margin signals rising operating or non-operating costs that erode converted profit from sales. If persistent, margin compression will weaken cash generation capacity, limit funding for R&D or dividends, and may require structural cost or pricing responses to restore profitability.
Significant Free Cash Flow Decline In 2025A sizable fall in free cash flow reduces available internal funds for investment, debt service, and shareholder returns. Over the medium term this can force trade-offs between R&D, capex and payouts, increase reliance on external financing, and constrain strategic execution if the trend persists.
Concentration In Japan And Women’s HealthHeavy reliance on the domestic Japanese market and a narrow therapeutic focus raises concentration risk to local regulatory changes, pricing reforms, and competitive entrants. Limited geographic and therapeutic diversification can amplify revenue volatility and constrain growth opportunities over the medium term.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥2942.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥61.93B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 60 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on Feb 02, 2026. The company reported ¥59.1 earnings per share for the quarter, beating the consensus estimate of N/A by ¥59.1.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥59.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.046%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---